FIGURE 3.

Investigator‐assessed PFS according to disease at baseline. Patients with measurable disease at baseline in the (A) BRCA‐mutated cohort, (B) HRD cohort, and (C) ITT population. Patients with nonmeasurable but evaluable disease at baseline in the (D) BRCA‐mutated cohort, (E) HRD cohort, and (F) ITT population. Patients with no disease at baseline in the (G) BRCA‐mutated cohort, (H) HRD cohort, and (I) ITT population. p values were nonsignificant for treatment by baseline disease subgroup interaction tests (BRCA‐mutated cohort: no disease vs. nonmeasurable disease, p = 0.3153; no disease vs. measurable disease, p = 0.2078; nonmeasurable disease vs. measurable disease, p = 0.6793; HRD cohort: no disease vs. nonmeasurable disease, p = 0.7447; no disease vs. measurable disease, p = 0.8119; nonmeasurable disease vs. measurable disease, p = 0.1317; ITT population: no disease vs. nonmeasurable disease, p = 0.4510; no disease vs. measurable disease, p = 0.1920; nonmeasurable disease vs. measurable disease, p = 0.3953). p values are presented for descriptive purposes only. CI indicates confidence interval; HR, hazard ratio; HRD, homologous recombination deficient; ITT, intent to treat; NR, not reached; PFS, progression‐free survival